Abstract library

10 results for "Kidneys".
#1388 Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate
Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Hendrik Bergsma
Authors:
#335 Dosimetry with 111In-octreotide and Coinfusion of Amino Acids in the Prediction of Nephrotoxicity in Neuroendocrine Tumors after PRRT with 90Y-DOTATOC
Introduction: Kidneys are the critical organs in PRRT. A dosimetry protocol was implemented in an ongoing study to estimate the biological effective dose (BED) on the kidneys after 90Y-DOTATOC therapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Sofie M.D.A. Van Binnebeek
Authors:
#781 Effect of Mean Absorbed Renal Dose on the Renal Function After Peptide Receptor Radionuclide Therapy
Introduction: Kidneys are the critical organs in peptide receptor radionuclide therapy (PRRNT) of neuroendocrine neoplasms (NENs).
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Harshad Kulkarni
Authors:
#698 Feasability of a Dosimetry Guided Therapy Planning for Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-Octreotate
Introduction: The efficacy and safety profile of PRRT can theoretically be optimized by planning each individual patient treatment on the absorbed dose to the critical organs and tumor lesions.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: PhD Mark W Konijnenberg
Authors:
Keywords: PRRT, dosimetry
#1817 Dosimetric Analyses of Patients with Metastatic Gastrointestinal Neuroendocrine Tumors Treated with PRCRT Using 177 Lu-DOTATATE with Capecitabine as Radiosensitizer
Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: DNB, FEBNM Sugandha Dureja
Authors:
Keywords: PRRT, radiosensitizer
#2014 Imaging of Advanced Medullary Thyroid Carcinoma with the CCK-2 Receptor Agonist 177Lu-PP-F11N – Preliminary Proof of the Principle within the “Lumed” Study
Introduction: Despite the introduction of new molecular targeted therapies, there is still an unmet need for an effective systemic therapy for advanced medullary thyroid carcinoma (MTC). Targeting the cholecystokinine-2 (CCK-2) receptor with radiolabeled gastrin analogues is a potential approach for radionuclide therapy of MTC.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Christof Rottenburger
Authors:
#1156 Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate
Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Dale Bailey
Authors:
#1251 Biodistribution and Radiation Dosimetry of a Novel 18F-Fluoroethyl Triazole [Tyr3] Octreotate Analogue for PET Imaging Patients with Advanced Neuroendocrine Tumours.
Introduction: Despite advances, detection and quantification of NET activity by imaging remains a challenge.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: DR Suraiya Dubash
Authors:
Keywords: PET
#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.
Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Catherine Lucas
Authors:
#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients
Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Enid Eslick
Authors: